Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Remember that the Wolf put you here
What is everyone thoughts on Sabby Capital?
Who own 40% of s/o
They seem to be Big time, although their AUM has been cut in half last few years
Starting to think it is Sabby, and not MM, having fun with the SP
It was exercised a few days after they missed the deadline for payment
It is the SEC filings somewhere
Which says to me 'were working with them' is a kind way of putting it. Nemus does not have the $ to sue though..
So since the company hasn't released anything the last while, were stuck in a uncertain time and I guess the SP reflects that
Last three months of the year Should be a wild ride
Fully diluted and including Series E financing
*.237
Citadel has a 173k bid at .273
Lots of liquidity if you want out
Not letting go of this one easily
'Valeant acquired Cesamet from Eli Lilly in 2004 and already sells the product in Canada, where it has about an 86% share of the cannabinoid market, accoridng to IMS data. It expects to launch Cesamet in the USA within the next few weeks.'
'Nabilone was originally developed by Eli Lilly and Company; Lilly received FDA approval in 1985 to market it, but withdrew that approval in 1989 for commercial reasons.[9] Valeant Pharmaceuticals acquired the rights from Lilly in 2004.[9] Valeant tried and failed to get the drug approved in 2005[10] and then succeeded in 2006.[9]'
Murphy CSO at VRX 2003-2006
DYODD
$4 a share would be a 440m market cap
420m EV
With a fully funded Phase 1 trial of NB1222/NB1111 and then positive results, we would be Off to the races. Look at $ZYNE at its Peak , much higher
And Look at GW. SPent a Lot of time on their first drug that WILL NEVER get approved in the USA as a medicine. Maybe one day as a rec product. And now a new Drug in Phase 3 trials, when asked about the science of your manufacturing you give toss a word salad and conclude with 'sorry about unscientific answer', and now doubt about whether the benefit of CBD is directly from the molecule or an interaction with other epilepsy drugs.
Still 1B market cap.
I have them Right between the eyes, whether they know it or not
And I hope $ZYNE goes higher but some People are probably pretty mad at Management
I'm not short either and wish them Good luck
Eddy Cast
We blowing out the float!
And the reverse Split is Fake news
They do not need to do one; to many potential catalysts that would take this SP to a level where they could uplist
They are a small cap biotech
No such thing as not enough money.
I doubt they have just been twiddling their thumbs for the last few months.
Will be an interesting end to the year to see where this goes in 2018
8's on the ask
Eddy cast owns the float!
Eddy cast
'We are blowing out the float!'
Helllo trips
if your answer to a question about the science involved in your product
involves 'why change something that we already believe works and works well' and 'Perhaps an unscientific answer'
You might want to rethink what you are Doing
DYODD
kinda dramatic
you bought the ticket, take the ride
If you need something to cheer you up, go read the conference call of Gover at MorganStanley conference
' So it’s more a question of why change something that we already believe works and works well.'
https://seekingalpha.com/article/4106691-gw-pharmaceuticals-gwph-ceo-justin-gover-presents-morgan-stanley-global-healthcare-conference?page=7
That attitude will work out Very well for them. "If you don't like change, you'll like irrelevancy worse."
Fully diluted, were nearing the EV of ZYNE
Matter of time before we Take the top spot
Day to day is just a mark
GLTFA
Someone just blew out 15m @ .0009
I really don't like it either. Bogart and Schneider are getting to Eric A I think...
What happened with Dr. Weinreb, vinpat? Hope you are well
Vinpat, how much damage did those traders do?
Has it been a headache dealing with that crap?
The guys who did it are getting sued by the SEC
https://www.sec.gov/litigation/complaints/2017/comp-pr2017-124.pdf
Nemus is named in the complaint, but is not listed as a part of the scam.
Very annoying. I had to go through all the defendants names in old SEC filings for Lock Guard and all the guys who were sold securities (no match).
28 days
Until Schneider needs to pay
No PR since Aug 7
I would think some sort of
Financial deals are occuring
just to be clear
I think Nemus has a monopoly when thinking about cannabinoid drug development. They stop doing pumps a Long time ago and they possess is the Real deal
It takes Courage but I like the jockeys and will get all my questions answered,.
just to be clear
I think Nemus has a monopoly when thinking about cannabinoid drug development. They stop doing pumps a Long time ago and they possess is the Real deal
It takes Courage but I like the jockeys and will get all my questions answered,.
Does InMed develop drugs or make drugs for other companies? What do they want to do????
Why do they continue to spend money on this stuff?
Teewinot has a Patented bio synthesis process for cannabinoids. Nemus chose them to manufacture their candidates.
So you have competition that has protected their IP.
FOCUS ON THE EB DRUG THE PUMPS MAKE ME SICK
No advisors have equity AFAIK
Never announced in PR or SEC filing
Maybe they couldn't afford the costs involved on retaining their services. Both of these hires were done when Hollister was there.
Also doesn't make sense with them transitioning to NB1222 lead
They don't do fake news
Or news for the sake of news
Last time they went this long without a PR, it was announcing the raise
They are working on it I would imagine
Why did Dr. Weinreb leave Nemus?
He appears in the PR until late 2015. Was supposed to head up a 'opthamology' board...
PR in 2016 said they had planned FDA pre-NDA meetings about NB1111. Did those happen? How often has Nemus met with the FDA?
It is new.
Because it discusses ZYNE recent failed read outs of ZYN002. Murphy takes the high road as well, considering what Vinpat had said about the company believing ZYNE would run into trouble with transdermal patches.
“Despite the failure, Zynerba should be commended for advancing the synthetic manufacturing of cannabinoids and also coming up with a novel way of getting the drug into the body, bypassing the liver, attempting to do it transdermally,” he added. “They will probably have to go back and reengineer the product. So we’ll have to wait and see what happens. But I think Zynerba should be commended anyways.”
It will be an interesting finish to the year for sure for NMUS regarding the financing and whether they file an IND (or two) before the page turns on 2017....
Nemus Bioscience CEO Talks 'Waves Of Dominance' In The Cannabis Therapeutics Industry
https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10002943/nemus-bioscience-ceo-talks-waves-of-dominance-in-the-ca
After what happened with their last raise, will their next offering be more or less advantageous to Inmed?
Think of
The money being spent on this
My favorite board in IHub
FDa getting ready to shut them down
CEO used to work at Worldcom (look it up)
And a 90 year old founder still accumulating shares, while forming LLC's with the CSO and CEO
Ostensibly to get the biz back up and running quick if the FDA gets to close
And the Longs give zero F's
I love it. A real window into what the human mind is capable of
GLTFA
Vinpat, while your here
The licensing agreements. The 60/40 split on revenue from potential sublicense fees, and the 5.5% Net fees royalty to UM, how does that compare to other deals between private/public entities? I have nothing to reference it to.
If a company just wanted to pay a bunch of cash, and no royalty, would UM be flexible if the money was right? Basically, and the agreements there to just protect both parties IP/investment or are they Strict agreements
Any financing rumours....?
Hope all is well
I finnaly found some info about one of Nemus founder(s)
Skibinski, who has just under 5% of the common stock, is running SnapMD (cloud based telemedicine technology allows for more efficient interaction between healthcare providers and patients) They just raised a few million and seem Not scam like.
Lapham, who is the biggest individual holder (and has never sold a share)...well....I found more than I bargained for
Can someone link me to
MIke Tomas blog?
The financing was set to close July 10th.
Schneider (financier) was given a 90 day extension. So were about halfway to the deadline, the company has not provided any guidance either way.
A few days after the 10th, Nemus also exercised the guaranty from entity tied to Schneider for the 20m.
Late September- early October we will know whether the deal is dead or not.
Regardless, should be able to complete a raise to file the INDs and start clinical trials in one of their candidates during first half of 2018
The series e financing delay
Is what has caused the downward pressure of the SP. And that it is tough to be a unknown and trading on the OTC
Once the Money has been figured out, a timeline should start to become firm for a IND for NB1222 and/or NB1111. Also, whether or not FDA will grant 502b pathway to NB1222 or not.
FDA saying they are going to remove red tape and become more open minded should help too.
What patents?
USRM has killed people
USRM has blinded people
GLTA longs....